SelectScience InterviewsLife Sciences
AI-driven high-throughput drug screening on patient-derived tumor organoids
1 May 2025
Dr. Christophe Deben (Group Leader, Tumoroid Screening Lab, University of Antwerp and co-founder of Orbits Oncology) presents DrugVision.AI, an AI-powered platform that combines robotic high-throughput screening of patient-derived tumor organoids with live-cell imaging. By integrating Orbits Oncology’s technology, the platform rapidly converts thousands of images into actionable drug response data. Dr. Deben shares a case study revealing a novel compound that boosts the effectiveness of current therapies, showcasing the potential of AI to advance precision oncology.
Tags
OrganoidsAIDrug ScreeningCancer ResearchCancer research aims to understand the mechanisms of cancer development and progression to improve prevention, diagnosis, and treatment. From molecular biology to clinical trials, research spans a wide range of disciplines, including immunotherapy, targeted therapies, and drug discovery. Explore the best cancer research products in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.